Scholarlink

<p>Sex-specific variations in lipid metabolism are largely influenced by hormonal factors. Compared to men, premenopausal women generally exhibit more favourable lipid profiles, such as higher levels of high density lipoprotein (HDL) and lower levels of low density lipoprotein (LDL). With the onset of menopause, these advantages diminish due to hormonal changes, leading to a significant increase in cardiovascular disease risk.</p><p>While lipid-lowering therapies are equally effective for both genders, studies indicate that women are less likely to achieve recommended LDL-cholesterin (LDL-C) targets. This gap is particularly pronounced in clinical practice, where there is often a&#xa0;significant disparity between guideline-based recommendations and actual treatment, especially for high-risk female patients. Factors contributing to this include an underestimation of cardiovascular risk in women and a&#xa0;lower prescription rate for statins. Moreover, women tend to discontinue therapies more frequently, partly due to a&#xa0;heightened perception of side effects and a&#xa0;greater prevalence of statin intolerance.</p><p>With treatment by specialists, many patients previously considered statin-intolerant can achieve successful treatment outcomes with targeted care. New lipid-lowering therapies and combination treatments offer alternatives to achieve therapeutic goals without relying solely on statins. However, even with these advancements, women often fail to meet LDL targets, underscoring the need for intensified care and gender-sensitive approaches.</p><p>Effective lipid therapy relies on the use of combination regimens, regular monitoring, and close collaboration between patients and healthcare providers. Improving therapy adherence and addressing potential barriers are particularly crucial for women to reduce cardiovascular risks more effectively.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Schlagen Frauenherzen anders? – Geschlechterunterschiede im Lipidmanagement

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月10日

查看全文
  • Maximilian Arne Muck,
  • Andrea Baessler

摘要

Sex-specific variations in lipid metabolism are largely influenced by hormonal factors. Compared to men, premenopausal women generally exhibit more favourable lipid profiles, such as higher levels of high density lipoprotein (HDL) and lower levels of low density lipoprotein (LDL). With the onset of menopause, these advantages diminish due to hormonal changes, leading to a significant increase in cardiovascular disease risk.

While lipid-lowering therapies are equally effective for both genders, studies indicate that women are less likely to achieve recommended LDL-cholesterin (LDL-C) targets. This gap is particularly pronounced in clinical practice, where there is often a significant disparity between guideline-based recommendations and actual treatment, especially for high-risk female patients. Factors contributing to this include an underestimation of cardiovascular risk in women and a lower prescription rate for statins. Moreover, women tend to discontinue therapies more frequently, partly due to a heightened perception of side effects and a greater prevalence of statin intolerance.

With treatment by specialists, many patients previously considered statin-intolerant can achieve successful treatment outcomes with targeted care. New lipid-lowering therapies and combination treatments offer alternatives to achieve therapeutic goals without relying solely on statins. However, even with these advancements, women often fail to meet LDL targets, underscoring the need for intensified care and gender-sensitive approaches.

Effective lipid therapy relies on the use of combination regimens, regular monitoring, and close collaboration between patients and healthcare providers. Improving therapy adherence and addressing potential barriers are particularly crucial for women to reduce cardiovascular risks more effectively.